ADAR and non-small cell lung carcinoma: ADAR family of enzymes was found to be the primary modulator of the frequency and number of sites edited in some cancers [18, 19] and ADAR1/2 dysregulation demonstrated extremely poor prognoses in non-small-cell lung cancer [20].